A clonal expression biomarker associates with lung cancer mortality.

Published on Oct 7, 2019in Nature Medicine30.641
· DOI :10.1038/s41591-019-0595-z
Dhruva Biswas1
Estimated H-index: 1
(UCL: University College London),
Dhruva Biswas1
Estimated H-index: 1
(UCL: University College London)
+ 32 AuthorsCharles Swanton66
Estimated H-index: 66
(UCL: University College London)
An aim of molecular biomarkers is to stratify patients with cancer into disease subtypes predictive of outcome, improving diagnostic precision beyond clinical descriptors such as tumor stage1. Transcriptomic intratumor heterogeneity (RNA-ITH) has been shown to confound existing expression-based biomarkers across multiple cancer types2–6. Here, we analyze multi-region whole-exome and RNA sequencing data for 156 tumor regions from 48 patients enrolled in the TRACERx study to explore and control for RNA-ITH in non-small cell lung cancer. We find that chromosomal instability is a major driver of RNA-ITH, and existing prognostic gene expression signatures are vulnerable to tumor sampling bias. To address this, we identify genes expressed homogeneously within individual tumors that encode expression modules of cancer cell proliferation and are often driven by DNA copy-number gains selected early in tumor evolution. Clonal transcriptomic biomarkers overcome tumor sampling bias, associate with survival independent of clinicopathological risk factors, and may provide a general strategy to refine biomarker design across cancer types. TRACERx Lung: Intratumoral transcriptional heterogeneity, which often hinders the development of clinically useful RNA-expression-biased biomarkers for cancer, can now be overcome with an approach for the identification of clonal expression biomarkers.
  • References (64)
  • Citations (3)
📖 Papers frequently viewed together
9 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Rachel Rosenthal (UCL: University College London)H-Index: 13
#2Elizabeth Larose Cadieux (Francis Crick Institute)H-Index: 1
Last. Charles Swanton (UCL: University College London)H-Index: 66
view all 28 authors...
The interplay between an evolving cancer and a dynamic immune microenvironment remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and histopathology-assessed tumour-infiltrating lymphocyte estimates. Immune infiltration varied both between and within tumours, with different mechanisms of neoantigen presentation dysfunction enriched in distinct immune microenvironments. Sparsely infiltrated tumours exhibited a waning of neo...
37 CitationsSource
#1Peng Jiang (Harvard University)H-Index: 11
#2Shengqing Gu (Harvard University)H-Index: 2
Last. X. Shirley LiuH-Index: 83
view all 15 authors...
Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in tumors with high infiltration of cytotoxic T lymphocytes (CTL) and the prevention of T cell infiltration in tumors with low CTL level. We identified signatures of T cell dysfunction from l...
55 CitationsSource
#1Diether Lambrechts (Katholieke Universiteit Leuven)H-Index: 71
#2Els Wauters (Katholieke Universiteit Leuven)H-Index: 10
Last. Bernard Thienpont (Katholieke Universiteit Leuven)H-Index: 29
view all 18 authors...
Cancer cells are embedded in the tumor microenvironment (TME), a complex ecosystem of stromal cells. Here, we present a 52,698-cell catalog of the TME transcriptome in human lung tumors at single-cell resolution, validated in independent samples where 40,250 additional cells were sequenced. By comparing with matching non-malignant lung samples, we reveal a highly complex TME that profoundly molds stromal cells. We identify 52 stromal cell subtypes, including novel subpopulations in cell types hi...
95 CitationsSource
#1Won-Chul Lee (University of Texas MD Anderson Cancer Center)H-Index: 18
#2Lixia Diao (University of Texas MD Anderson Cancer Center)H-Index: 35
Last. Jianjun Zhang (University of Texas MD Anderson Cancer Center)H-Index: 20
view all 23 authors...
Intra-tumor heterogeneity may be present at all molecular levels. Genomic intra-tumor heterogeneity at the exome level has been reported in many cancer types, but comprehensive gene expression intra-tumor heterogeneity has not been well studied. Here, we delineated the gene expression intra-tumor heterogeneity by exploring gene expression profiles of 35 tumor regions from 10 non-small cell lung cancer tumors (three or four regions/tumor), including adenocarcinoma, squamous cell carcinoma, large-...
8 CitationsSource
#1Valentine Svensson (EMBL-EBI: European Bioinformatics Institute)H-Index: 12
#2Sarah A. Teichmann (University of Cambridge)H-Index: 76
Last. Oliver Stegle (EMBL-EBI: European Bioinformatics Institute)H-Index: 47
view all 3 authors...
SpatialDE identifies genes with significant spatial expression patterns from multiplexed imaging or spatial RNA-sequencing data, and can cluster genes with similar spatial patterns as a form of expression-based tissue histology.
31 CitationsSource
#1Bernhard MlecnikH-Index: 9
#2Marc Van den EyndeH-Index: 8
Last. Jérôme Galon (Paris V: Paris Descartes University)H-Index: 64
view all 23 authors...
42 CitationsSource
#1Patrick Danaher (NanoString Technologies)H-Index: 6
#2Sarah Warren (NanoString Technologies)H-Index: 6
Last. Stephen P Fling (UW: University of Washington)H-Index: 1
view all 10 authors...
Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the intratumoral abundance of various immune cell populations with gene expression. In contrast to IHC and flow cytometry, gene expression assays yield high information content from a clinically practical workflow. Previous studies of gene expression in purified immune cells have reported hundred...
54 CitationsSource
#1Brian Cleary (MIT: Massachusetts Institute of Technology)H-Index: 7
#2Le Cong (Broad Institute)H-Index: 16
Last. Aviv Regev (MIT: Massachusetts Institute of Technology)H-Index: 110
view all 5 authors...
Summary RNA profiles are an informative phenotype of cellular and tissue states but can be costly to generate at massive scale. Here, we describe how gene expression levels can be efficiently acquired with random composite measurements—in which abundances are combined in a random weighted sum. We show (1) that the similarity between pairs of expression profiles can be approximated with very few composite measurements; (2) that by leveraging sparse, modular representations of gene expression, we ...
27 CitationsSource
#1Billy W. Loo (Stanford University)H-Index: 39
#2Yi Cui (Stanford University)H-Index: 18
Last. Ruijiang Li (Stanford University)H-Index: 25
view all 4 authors...
Importance The prevalence of early-stage non–small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy. Objective To develop a robust, individualized immune signature that can estimate prognosis in patients with early-stage nonsquamous NSCLC. Design, Setting, and Participants This retrospective study analyzed the gene express...
27 CitationsSource
#1Mathias Uhlén (KTH: Royal Institute of Technology)H-Index: 93
#2Cheng Zhang (KTH: Royal Institute of Technology)H-Index: 15
Last. Fredrik Pontén (Uppsala University)H-Index: 58
view all 27 authors...
Cancer is one of the leading causes of death, and there is great interest in understanding the underlying molecular mechanisms involved in the pathogenesis and progression of individual tumors. We used systems-level approaches to analyze the genome-wide transcriptome of the protein-coding genes of 17 major cancer types with respect to clinical outcome. A general pattern emerged: Shorter patient survival was associated with up-regulation of genes involved in cell growth and with down-regulation o...
392 CitationsSource
Cited By3
#1Zayd Tippu (The Royal Marsden NHS Foundation Trust)H-Index: 1
#2Lewis Au (The Royal Marsden NHS Foundation Trust)H-Index: 3
Last. Samra Turajlic (The Royal Marsden NHS Foundation Trust)H-Index: 23
view all 3 authors...
Abstract A diverse range of clinical phenotypes are observed in clear-cell renal cell carcinoma (ccRCC) with resultant therapeutic implications. Molecular characterisation underpinning the diversity observed has been qualified, where the near ubiquitous loss of the short arm of chromosome 3 precedes distinct evolutionary trajectories involving different sequences and combinations of genetic events. Primary tumours are characterised by varying degrees of intratumoural heterogeneity and chromosoma...
#2Amelia Insa (University of Valencia)H-Index: 7
Last. Andrés CervantesH-Index: 56
view all 4 authors...
The introduction of new high-throughput technologies in oncology and the need to apply precision medicine for cancer patients has led to the detection of several molecular alterations. Among them, activating mutations of ERBB2 have been reported in many solid tumours. In the last years, several clinical trials with covalent tyrosine kinase inhibitors (TKIs) for ERBB2 mutant cancers have been conducted, with different results among several cancer types. In the SUMMIT trial, neratinib was most eff...